Biotech company Pharming Group NV (“Pharming” or “the Company”)  announced that recombinant human C1 esterase inhibitor (rhC1INH; RUCONEST®), an investigational drug in the U.S., has been shown to have a beneficial effect as a donor pre-treatment therapy in an animal model of kidney trans

read more>>

Cellular Biomedicine Group announced that it has achieved half of the enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most

read more>>

The Leukemia & Lymphoma Society (LLS) is committing approximately $6 million to Valor Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber, to co-fund the completion of pre-clinical development, manufacturing, and a Phase I clinical trial for a novel fusion protein that may change V

read more>>

Every day, their baby stopped breathing, his collapsed bronchus blocking the crucial flow of air to his lungs. April and Bryan Gionfriddo watched helplessly, just praying that somehow the dire predictions weren't true"Quite a few doctors said he had a good chance of not leaving the hospital alive

read more>>

Neuralstem, Inc. reported that Eva Feldman, MD, PhD, principal investigator, presented updated Phase I data from its spinal cord-derived human neural stem cell (NSI-566) trial in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at the neuro diabetes special medical Dr.

read more>>

Grifols, a global healthcare company based in Barcelona, Spain, presented results from a study demonstrating that a higher dose of PROLASTIN©-C (Alpha1-Proteinase Inhibitor [Human]) increased levels of the alpha1 protein in patients with alpha1antitrypsin (AAT) deficiency to levels that are Resul

read more>>

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on lung function and the safety of a range of doses in patients with moderate to severe PSX10

read more>>

Agenus Inc. announced enrollment has started for a large, randomized Phase 2 study of Prophage G-200 (Heat Shock Protein Peptide Complex-96 or HSPPC-96) vaccine in combination with bevacizumab (Avastin®) for treatment of recurrent glioblastoma multiforme (GBM) in adult patients. The study is being

read more>>

Rigel Pharmaceuticals, Inc. announced the clinical advancement of three programs in development. The first program is a wholly-owned topical ophthalmic formulation of a JAK/SYK inhibitor, R348, being developed by Rigel as a treatment for dry eye disease. The other two programs are aimed at oncology

read more>>

Oncolytics Biotech Inc. ("Oncolytics") announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 020). The Principal Investigator is Dr. Devalingam Eligi

read more>>